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At the hospital, the pharmacist is constantly challenged to prepare extemporaneous solutions from tablets, 
capsules or drug powder for patients unable to swallow, such as pediatric, elderly and patients that use 
nasoenteric and nasogastric tubes. The preparation of extemporaneous solutions from capsules, tablets 
and drug powder requires stability studies analysis. This article is a bibliographic review of preparation 
of extemporaneous oral liquid from solid oral dosage forms used in clinical practice. The selected articles 
contain all the information regarding manipulation techniques, pharmaceutical excipients, packaging, 
storage conditions and results of stability studies above 90% performed by HPLC analysis. In addition, 
a situational analysis of the strategies for the preparation of the extemporaneous solution was described 
to help the manipulator in the decision. The preparation of extemporaneous solution from solid oral 
dosage forms is based on information from official compendium or scientific literature, to ensure safe 
and effective manipulated medicine.
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INTRODUCTION
A large part of the therapeutic arsenal consists 
of solid oral dosage forms such as tablets and capsules 
available for most patients, including hospitalized patients. 
However, pediatric, elderly and patients that must receive 
medications via nasogastric or gastrostomy tubes are 
unable to swallow solid oral dosage forms. One way to 
solve this problem is the preparation of extemporaneous 
solutions from solid oral dosage forms commercially 
available in the national and international markets 
(pharmacy and hospital pharmacy), for example, through 
tablets trituration or capsules opening and subsequent 
addition of water or another vehicle. However, there is 
difficulty in masking the unpleasant taste of the solution 
and reach the uniformity of the dose ensuring the correct 
dose. In addition, information in the literature about 
stability, storage conditions, packaging and handling 
technique for the preparation of the extemporaneous 
formulations is limited.
The risk of preparation of oral liquid formulations, 
such as formulation failure, microbial contamination, 
calculation errors, starting materials, patient acceptability, 
health safety risks and associated clinical risk factors, 
according to the place of preparation. The highest risk 
occurs when oral liquid formulations are prepared in the 
wards for nursing technician. The risk in the preparation 
tends to decrease when pharmacists in compounding 
pharmacies prepare the oral liquid formulations. The risk is 
even lower when oral liquid formulations are prepared by 
the pharmaceutical industry and the products are licensed 
and registered in the regulatory agencies. The technical and 
clinical risks associated with extemporaneously prepared 
medicines are considered below (Jackson, Lowey, 2010):
1 - Formulation failure: All formulae used for 
extemporaneous preparation should be validated 
and have supporting stability data. Suitable sources 
include pharmacopoeia formulations, industry expert 
reports and published papers. The causes of oral liquid 
formulation failure can be complex, including physical 
incompatibilities, interaction drug and excipient and 
drug degradation (oxidation, photo-degradation, 
hydrolysis, dimerization, polymerization). 2 - Microbial 
contamination: Microbial contamination may pose a 
significant risk to immunocompromised patients. In 
addition, the products of microbial degradation can 
lead to chemical changes in the preparation. Microbial 
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growth can cause preparation turbidity and unpleasant 
odor. The choice of preservative for a formulation needs 
to take into account a number of factors, including pH, 
physical compatibility and the patient group. Oral liquid 
preparations without preservative should be stored in 
a refrigerator with a maximum shelf life of 7 days at 
2-8 °C (Jackson, Lowey, 2010). 3 - Calculation errors: 
Calculation errors pose the greatest risk of causing serious 
patient harm and the greater the complexity of calculation 
required, the higher the risk of an error. Formulations 
should be kept as simple as possible and all calculations 
should be independently checked and documented on a 
worksheet (Jackson, Lowey, 2010). 4 - Starting materials: 
The toxicity of some ingredients is age-specific and they 
may be inappropriate for children. Alcohol has been linked 
to CNS-depressant and hypoglycemic effects. Pediatrics 
formulations containing sugars have been associated 
with dental cavities. 5 - Patient acceptability: Oral liquid 
formulation should be palatable with good presentation. 
There is a good argument that taste is crucial to achieving 
good compliance in children. 6 - Health and safety risks: 
The risks to the operator should also be considered. 
Hospital pharmacy should be equipped with laminar flow 
when handling hazardous products. Good manipulation 
practices should be put in place to eliminate the risk of 
cross-contamination. 7 - Associated clinical risk factors: 
The majority of patients that receive extemporaneously 
prepared oral liquid formulation tend to be from vulnerable 
patient groups like neonates, children and the elderly, 
who are either unaware of ill-effects associated with 
their treatment or who cannot communicate with their 
clinician. Pharmacists should take into account the 
patients who receive extemporaneous preparations and 
regularly review their condition to ensure the treatment is 
effective. Any issues should be documented and reported 
to the manufacturer as part of a pharmacovigillance action 
(Jackson, Lowey, 2010).
The lack of pediatric products available on the 
market is related to: 1 - very small size of pediatric 
market compared to adults, especially medicines used to 
treat hypertension, tuberculosis, neoplasias and acquired 
immunodeficiency syndrome (Glass, Haywood, 2006); 
2 - difficulties in performing clinical trials in children 
(Méndez et al., 2006); 3 - slow financial return and 4 - high 
requirements proposed by regulatory agencies for the 
development and registration of pediatric medicines that 
discourage the pharmaceutical industry (Glass, Haywood, 
2006; Méndez et al., 2006; Nahata, 1999; Jackson, Lowey, 
2010).
The unavailability of pharmaceutical form and 
dosage for pediatric patients challenges the pharmacy 
manipulator to triturate the tablet and adjust the dosage to 
a solid form (capsule or sachet) or liquid form (solution 
or suspension) for oral use (Martinho, Guerreiro, Simon, 
2010; Brion, Nunn, Rietour, 2003). Therefore, the tablet 
must be triturated and the dosage adjustment made for 
safe administration to the patient (Mcdevict, Gurst, Chen 
1998; Horn, Kuhn, Kanga, 1999; Pinto, Barbosa 2008; 
Doningos, 2010). The pharmacist should perform an 
analysis before triturating the tablet to adjust the dose 
by turning it into powder which will be used to fill a 
capsule or to prepare in a liquid form. The trituration from 
tablet or modified release capsule (delayed or extended-
release) causes immediate release of the dose after oral 
administration, with the risk of adverse effects, toxicity or 
even pharmacological action loss, if the drug is sensitive 
to destruction by stomach acidity (Glass, Haywood, 2006; 
Nahata, 1999). The use of injectable solution for the 
preparation of the oral liquid solution is discouraged due 
to some of the following problems: drug or vehicle with 
mucosal, vesicant and irritant (Firas et al., 2016), extensive 
hepatic metabolism may reduce the bioavailability of the 
drug at subtherapeutic concentrations (Woods, 1997), 
drug with very low absorption in the intestinal mucosa 
(Hailong et al., 2014) and stomach acid and digestive 
enzymes may degrade the drug avoiding intestinal 
absorption (Perera et al., 2009).
Health professionals in pediatric hospitals usually 
promote tablets trituration in a mortar or capsules 
opening by dissolving the powder in single syrup or 
sorbitol mixture (Nahata, 1999). When an oral medicine 
is formulated for pediatric use, several factors should be 
considered, such as; gastrointestinal tract immaturity, 
reduced biliary secretion, and slow gastric emptying that 
may alter the absorption of many drugs (Glass, Haywood, 
2006; Méndez et al., 2006). Many excipients such as 
preservatives, sweeteners and co-solvents of oral liquid 
formulations can cause problems for neonates. 
Benzyl-alcohol syndrome has since become a 
recognized event in premature infants (Brown, Buist, 
Gepson, 1982). The normal metabolic pathways for 
benzyl- alcohol in adults are immature in premature infants, 
leading to the accumulation of benzyl-alcohol and benzoic 
acid. One of the most common preservative systems used 
is a combination of hydroxybenzoates also known as 
parabens. This preservative system can worsen asthma 
and has also been shown to promote hypersensitivity 
reactions (Golightly et al., 1988). Propylene glycol 
may also acts as an osmotic laxative. Preparations that 
contain large quantities may not, therefore, be suitable for 
neonates and young children. Ethanol is known to have 
a CNS depressant effect, and its use is avoided wherever 
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possible in extemporaneous preparations. However, 
limited quantities of ethanol may be justifiable under 
some circumstances, in order to prevent the use of other 
co-solvent systems associated with known toxicities. 
The use of preparations that contain sugars, especially 
sucrose, are associated with the formation of dental 
cavities, particularly with long-term use (Jackson, Lowey, 
2010). Table I summarizes some excipients that when 
administered to pediatric patients may possibly cause 
rash, contact dermatitis, angio dermatitis and respiratory 
syndrome, allergic reactions, adverse effects in patients 
intolerant to fructose with hypoglycemic effects, liver 
damage and coma, diarrhea due to the osmotic effect, lactic 
acidosis, renal failure, central nervous system depression, 
hyperglycemia in diabetic patients and cavities and others 
(WHO, 2011a; Cuzzolin, 2018; EMEA, 2013; Jackson, 
Lowey, 2010). 
The elderly population and children have difficulty 
in ingestion of solid oral dosage forms. Thus, caregivers 
of elderly and hospital nurses usually promote tablets 
trituration and sprinkle powders on food. The aim of this 
practice is to supply the necessary medicines to elderly 
patients and children; however, there are problems in this 
practice. Administration of triturated tablets with food is 
worrisome due to the physical-chemical interaction of 
the drug in the stomach acid environment. Simultaneous 
trituration of various types of tablets should be avoided to 
prevent pharmacodynamic and pharmacokinetic problems 
(Rasgado, 2009; Paradiso, 2002).
Administration of a solid oral dosage form through 
nasogastric tube needs transformation into oral liquid 
form using a suitable vehicle, for example; aqueous 
solution with low viscosity to prevent the clogging of 
nasogastric tube. The use of nasogastric tube for drugs 
administration may alter the bioavailability of the drug 
through its interaction with the material constituting 
the nasogastric tube. In addition, tablets trituration may 
produce particles or crystals by precipitation blocking 
the nasogastric tube. The knowledge of the interaction 
of the drug with the material constituting the nasogastric 
tube may avoid problems. Some drugs have affinity for 
the material constituting the nasogastric tube leading 
to the adsorption of the drug or the permeation to the 
tube decreasing the dose of the drug to the patient; 
for example carbamazepine, which is adsorbed on the 
nasogastric tube (Rebecca, Vicky, 2015; Silva, Lisboa, 
2011; Hoefler, Vidal, 2009; Willians, 2008). Delayed-
release tablets, capsule-containing granules with gastro-
resistant coating, sustained-release and controlled-
release tablets should not be triturated (Table II). The 
gastro-resistant dosage forms for intestinal release 
when triturated and ingested with aqueous solution, 
exposes the drug to acidity of the stomach causing its 
inactivation. Trituration of an extended or controlled 
release tablet leads to immediate release of the drug 
exposing the patient to high dosages or exacerbation of 
adverse effects. Table II contains examples of solid oral 
dosage that should not be triturated. Information on the 
modified release systems of Table II are contained in the 
patient’s information chart.
The objective of this work was to carry out a 
bibliographic review for preparation of extemporaneous 
solutions from the solid oral dosage forms for use in 
clinical practice. The choice of drugs was based on the lack 
of extemporaneous oral liquid form. All selected articles 
contained the following terms: manipulation techniques, 
excipients, packaging, storage conditions and stability 
studies results above 90% analyzed by HPLC.
TABLE I - Some excipients, when administered to pediatric 
patients, may cause health risk (WHO, 2011a; Cuzzolin, 2018; 
EMEA, 2013; Jackson, Lowey, 2010)
Excipients Inherent risk for the pediatric patient
Benzyl Alcohol, Benzoic 
acid and Sodium benzoate
Children less than 3 years old 
may develop rash, contact 
dermatitis, angiodermatitis and 
respiratory syndrome.
Dye Allergic and other reactions.
Sodium cyclamate and 
Saccharin sodium
High sodium concentrates 
are not recommended for 
hypertensive and renal 
patients.
Ethanol Depression of the central nervous system 
Methylpaben and 
Propylparaben Elevation of bilirubin
Propylene glycol
Diarrhea due to osmotic 
effect, lactic acidosis, renal 
failure, central nervous system 
depression.
Polysorbate 80 Metabolic acidosis, liver dysfunction and cholestasis.
Sucrose Hyperglycemia in diabetic patients and cavities.
Sorbitol
Adverse effects in patients 
intolerant to fructose with 
hypoglycemic effects, liver 
damage and coma.
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Methodology
A literature review was carried out observing 
publications available in the Medline (International 
Literature in Health Sciences), Lilacs (Latin American 
and Caribbean in Health Sciences) and Scientific 
Electronic Library Online (SCIELO) databases 
between 1990 and 2017.  The terms used were: 
“extemporaneous formulations”, “extemporaneous 
oral liquid”, “extemporaneous preparation”, “stability 
of extemporaneous formulations”, “extemporaneous 
preparation for children”, “medication administration 
through enteral feeding”. After reading abstracts of the 
collected papers, only articles containing the preparation 
method, materials and stability studies of extemporaneous 
solutions from solid oral dosage forms commercially 
available were selected. Because it is the most common 
situation found in clinical practice.
RESULTS AND DISCUSSION
Results of the bibliographic review are described 
below, demonstrating the most common preparation of 
extemporaneous solutions from solid oral dosage forms 
used in clinical practice. The selected articles contain 
all the information regarding manipulation techniques, 
excipients, packaging, storage conditions and stability 
studies results above 90% performed by HPLC analysis. 
Table III contains preparations of extemporaneous 
solutions from solid oral dosage forms commercially 
available, mentioning the drug, storage conditions, 
stability and references. Details from descriptions of 
the preparation method, pharmaceutical excipients 
and packaging are described through viewing the 
selected articles. Some drugs have been selected for 
a detailed description such as: captopril, carvedilol, 
diltiazem, enalapril, lisinopril, metoprolol, moxifloxacin, 
TABLE II - Oral solid pharmaceutical forms that cannot be triturated and modified
Medicines Drug Pharmaceutical form Comments
Actonel Risedronate Film-coated tablet Tablets, when triturated, may cause 
oropharyngeal irritation
Adalat OROS Nifedipine Osmotic pump tablet Extended-release tablet
Allegra D Fexofenadine hydrochloride and 
Pseudoephedrine hydrochloride
Film-coated tablet Extended-release tablet
Cardizem Diltiazem hydrochloride Tablet Extended-release coating tablet
Cardizem CD Diltiazem hydrochloride Capsule Extended-release tablet
Cipro XR Ciprofloxacin Film-coated tablet Extended-release tablet
Claritin D Loratadine and Pseudoephedrine Tablet Extended-release tablet
Claritin D 24h Loratadine and Pseudoephedrine Film-coated tablet Extended-release tablet
Depakene Valproic acid Capsule Extended-release tablet. When 
triturated, may causes mucous 
irritation
Erythromycin stearate Erythromycin stearate Tablet Enteric coating for delayed release
Feldene Piroxicam Capsule Irritant of mucous
Isordil sublingual Isosorbide Tablet (sublingual) Not triturate. Sublingual release
Isotretinoin Isotretinoin Capsule Not open. Irritant to mucous
Kaletra Lopinavir and Ritonavir Tablet Film-coated to prevent direct 
patient contact with drugs to avoid 
cross-contamination
Metri Nicotinic acid Film-coated tablet Extended-release tablet
Ritalina La Methylphenidate Capsule Extended-release tablet
Xanax XR Alprazolam Tablet Extended-release tablet
XigDuo XR Dapagliflozin + metformin 
hydrochloride
Film-coated tablet Extended-release tablet
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TABLE III - Extemporaneous oral liquid prepared from solid oral dosage forms commercially available
Drug Stability of liquid oral form References
Acetazolamide 60 days at 25 °C and 40 °C Santoveña et al., 2016b
Alprazolam 60 days at 25 °C Allen, Erickson, 1998
Amlodipine 1 year at 4 °C in absence of light Vossen et al., 2016
Aripiprazole 91 days at 4 °C Pramann et al., 2016
Atorvastatin 30 days at 8 °C or 25 °C Zaid et al., 2016
Bosentan 31 days at 21-26 °C Malik et al., 2016
Capecitabina 14 days at 8 °C in absence of light Romero et al., 2016
Captopril 45 days at 5 °C Dysarz, 2017
Carbidopa 30 days at 20-25 °C and 90 days at 2-8 °C Polonini et al., 2016b
Carvedilol 8 weeks at 22-26 °C or 4-8°C Yamreudeewon, Dolence, Pahl, 2006
Celecoxib 90 days at 40 °C Kiel et al., 2016
Chloroquine 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Chlorpromazine 90 days at 2-8 °C or 22-25 °C Prohotsky, Juba, Zhao, 2014
Cinacalcet 64 days at 2-8 °C or 22-25 °C in absence of light Thomson, Hutchinson, Chablani, 2018
Cholecalciferol 90 days at 2-8 °C or 20-25 °C Polonini et al., 2016b
Clobazam 56 days at 4 °C or 25 °C Buontempoa et al.,2013
Clomipramine 90 days at 5 °C or 25 °C Polonini et al., 2016a 
Clonazepam 60 days at 5 °C or 25 °C Allen, Erickson, 1996b
Clonidine 91 days at 4 °C or 25 °C Ma, Decarie, Ensom, 2014; 
Ensom, Decarie, 2014
Dapsone 91 days at 4 °C or 25 °C Nahata, Morosco, Trowbridge, 2000
Diazoxide 90 days 5 °C or 25 °C in absence of light Friciu et al., 2016b
Diltiazem 60 days at 5 °C or 25 °C Allen, Erickson, 1996a
Enalapril 30 days at 25 °C in absence of light Sosnowska, 2009
Erlotinib 28 days at 25 °C in absence of light Li et al., 2016
Flecainide 30 days at 25 °C in absence of light Santoveña et al., 2016a
Folicacid 90 days at 5 °C and 25 °C Polonini et al., 2016a
Furosemide 270 days at 25 °C at 40 °C Zahálka et al., 2017
Gabapentin 90 days at 25 °C Friciu, Roullin, Leclair, 2017
Glibenclamide 90 days at 4 °C, 25 °C or 40 °C Estevez et al., 2016
Haloperidol 90 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Hydrochlorothiazide 90 days at 5 °C or 25 °C Poloniniet al., 2016a
Idebenone 90 days at 5 °C or 25 °C in absence of light Schlatter et al, 2017
Imatinib 14 days at 5 °C or 25 °C in light or absence of light Li et al., 2016
Imipramine 90 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Isotretinoin 6 months at 40-42 °C Montwani, Isloor, Arora, 2015
Lapatinib 28 days at 25 °C Li et al., 2016
Levodopa 30 days at 20-25 °C and 90 days at 2-8 °C Polonini et al., 2016b
Levofloxacin 57 days at 23-25 °C Vanden Bussche et al., 1999
Lisinopril 4 weeks at ≤ 25 °C Thompson et al., 2003
Loperamide 90 days at 5 °C or 25 °C Polonini et al., 2016a
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Drug Stability of liquid oral form References
Lorazepam 60 days at 22-25 °C Polonini et al., 2016b
Melatonin 90 days at 3-5 °C and 23-27 °C Friciu et al., 2016a
Metformin 30 days at 4-40 °C in the presence or absence of light Alemon-Medina et al., 2014
Methadone 90 days at 4 °C and 25 °C Provenza et al., 2016
Methotrexate 90 days at 5 °C or 25 °C Polonini et al., 2016ª
Metoprolol 8 weeks at 22-26 °C or 4-8°C Yamreudeewong, Dolence, Pahl, 2006
Minocycline 10 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Minoxidil 10 weeks at 2-4 °C in absence of light Song et al., 2018
Moxifloxacin 90 days at 23-25 °C Hutchinson, Johnson, Klein, 2009
Nadolol 90 days at 5 °C or 25 °C Polonini et al. 2016a 
Naltrexone 90 days at 5 °C or 25 °C Polonini et al., 2016a 
Naproxen 91 days at 4 °C and 25 °C Ensom, Decarie, Lingertat-Walsh, 2015
Norfloxacin 56 days at 23-25 °C Johnson, Price, Hession, 2001
Oseltamivir 35 days at 5 °C or 25 °C or 13 days at 30 °C Winiarski et al., 2007 
Pentoxifylline 90 days at 5 °C or 25 °C Polonini et al., 2016ª
Phenobarbital 60 days at 4 °C and 30 days at 25 °C Provenza et al., 2016
Phenytoin 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Propafenone 90 days at 3-5 °C or 15±5 °C Olguín, 2008
Propranolol 120 days at 25 °C and 4 °C Ensom et al., 2013
Pyridoxine 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Quinapril 6 weeks at 5 °C Freed et al., 2005
Ribavirin 28 days at 4 °C Chan, Tong, Chow, 2004
Saquinavir 20 days at 5 °C or 25 °C Tan, Thenmozhiyal, Ho, 2003
Sildenafil 91 days at 4 °C or 25 °C Nahata, Morosco, Brady, 2006
Sotalol 180 days at 5 °C or 25 °C in absence of light Klovrzová et al., 2016
Sulfadiazine 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Sulfasalazine 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Tacrolimus 90 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Terbinafine 90 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Tetracycline 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
Tiagabine 70 days at 25 °C Nahata, Morosco, 2003
Topiramate 90 days at 2-8 °C Allen, 2017
Trimethoprim 90 days at 2-8 °C at 20-25 °C Ferreira et al., 2016
Vancomycin 91 days at 4 °C or 25 °C Smith et al., 2017
Valsartan 90 days at 2-8 °C or 22-25 °C Polonini et al., 2016b
Warfarin 30 days at 25 °C and 45 days at 4 °C Schlatter, Cisternino, 2017
Zonisamide 90 days at 2-8 °C or 20-25 °C Ferreira et al., 2016
TABLE III - Extemporaneous oral liquid prepared from solid oral dosage forms commercially available (cont.)
propafenone and ribavirin. These medications were 
selected as being the most commonly dispensed in clinical 
practice, in accordance with extensive bibliographic 
review from literature. 
All oral liquid formulations with stability > 
90% were considered. Content and stability (%) 
were determined by HPLC (High performance liquid 
chromatography),metoprolol
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Captopril
Captopril was the first angiotensin converting enzyme 
(ACE) inhibitor that was marketed. Administered orally, 
it is rapidly absorbed and has a bioavailability of about 
75%. It is widely used in the treatment of hypertension, 
cardiac insufficiency, myocardial infarction and diabetic 
nephropathy in patients with insulin-dependent diabetes 
mellitus (Dysarz, 2017). In the Brazilian market, this drug 
is only available in the solid oral dosage form (tablets). 
In a work performed by Dysarz (2017), it was developed 
an extemporaneous solution of captopril (5 mg/mL) and 
the stability of the extemporaneous solution evaluated. 
The formulation containing captopril (5 mg/mL), EDTA, 
sodium saccharin and water stored in amber glass bottles 
and stored at 5 °C refrigerator temperature was stable for 
45 days maintaining the content of the drug (> 90%) and 
degradation product within the Brazilian pharmacopoeia 
limits (Dysarz, 2017). The stability of 0.75 mg/mL 
captopril extemporaneous oral liquid prepared from 
tablet was studied by Allen and Erickson. One tablet of 
100 mg was pulverized and the powder comminuted in a 
mortar with a pestle. The vehicle used was a 1:1 mixture 
of Ora-Sweet:Ora-Plus and 1:1 mixture of Ora-Sweet 
SF:Ora-Plus, both with initial pH of 4.1. The quantity 
of vehicle was qs 134 mL. A portion of the vehicle was 
used to levigate the powder and a uniform paste prepared. 
Additional vehicle was added to the mortar in small 
portions and rinsed repeatedly. The product was placed 
in an amber clear plastic (polyethylene terephthalate) and 
fitted with caps lined with low-density polyethylene foam. 
Three bottles were stored at 5 °C and three bottles at 25° in 
the absence of light. The samples were analyzed from each 
individual bottle after 1, 2, 7, 10, 14, 28, 35 and 60 days. 
The oral liquids were examined at each sample time and 
there was no change in appearance or odor. The solution 
remained stable for 7 days at 25 °C or 14 days at 5 °C for 
the Ora-Sweet:Ora-Plus vehicle and 5 days at 25 °C or 
10 days at 5 °C for the Ora-Sweet SF and Ora-Plus. The 
concentration of captopril found was above 90% (Allen, 
Erickson, 1996a).
Enalapril
Sosnowska et al. investigated the stability of 
0.1 mg/mL and 10 mg/mL enalapril maleate extem-
poraneous suspensions prepared from commercially 
available tablets. Enalapril maleate is a prodrug, with no 
direct biological activity. It is quickly absorbed after oral 
and hydrolyzed in vivo into its active form, enalaprilate, 
a potent inhibitor of the angiotensin converting enzyme 
(ACE). It is widely used in adult and pediatric patients 
to treat hypertension and cardiac insufficiency. For the 
extemporaneous preparation the tablets were triturated 
to a fine powder and mixed with a solution of 0.5% 
hydroxyethyl cellulose, then, it was added a mixture of 
raspberry syrup and hydroxyethyl cellulose solution, 5% 
(1:10). Raspberry syrup was used to mask the unpleasant 
taste of enalapril maleate. In both formulations 0.2% 
of methyl hydroxybenzoate was added as preservative. 
Enalapril maleate is stable at pH close to 3.0, the pH 
values of the formulations were adjusted to 3.0 using 
citric acid (1mol L-1). The suspensions were stored in 
amber glass flasks at 25 °C in the absence of light. After 
30 days of storage, the enalapril maleate concentration was 
98% and there were no significant changes in viscosity 
and pH of the suspensions (Sosnowska, 2009). Allen 
and Erickson studied the stability of 1 mg/mL enalapril 
maleate extemporaneous oral liquid prepared from tablets. 
The extemporaneous oral liquids were prepared by tablet 
trituration and added in a 1:1 mixture of Ora-Sweet 
and Ora-Plus and 1:1 mixture of Ora-Sweet SF and 
Ora-Plus and placed in 120 mL amber, clear polyethylene 
terephthalate bottles. The extemporaneous oral liquids 
were stored at 25 °C and 5 °C, in the absence of light. 
After 60 days of storage, the enalapril maleate initial 
drug concentration was at least 91% and there were no 
substantial changes in the appearance, odor, or pH of any 
liquid observed (Allen, Erickson, 1998). 
Carvedilol
In a study carried out by Yamreudeewonget, Dolence 
and Pahlthe (2006), the stability of extemporaneous 
solutions of carvedilol was analyzed. Carvedilol is a 
non-selective β-adrenergic receptor antagonist and a 
α1-selective α-adrenergic receptor antagonist, and exhibits 
anti-anxiety properties. The drug is used in the treatment 
of congestive heart failure, angina pectoris and high blood 
pressure. The preparation method of extemporaneous 
solution of carvedilol 25 mg was developed using three 
tablets of caverdilol 25 mg, which were triturated and 
mixed with 20 mL deionized water to form a paste. It 
was added 40 mL of 70% sorbitol solution and sufficient 
amount of deionized water to obtain a final volume of 
120 mL. The concentration of carvedilol in the mixture 
was approximately 0.625 mg/mL. Part of the solution was 
stored in an amber PET bottle at 22-26 °C and another part 
at 4-8 °C. For eight weeks the solutions remained stable. 
The concentration of carvedilol found was ± 10% of the 
initial concentration (Yamreudeewonget, Dolence, Pahl, 
2006). 
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Diltiazem
Diltiazem hydrochloride is a calcium channel 
antagonist, used primarily to prevent angina pectoris, 
but it is also used in cases of coronary heart disease with 
tachycardia and arterial hypertension. Allen and Erickson 
(1996a) studied the stability of diltiazem hydrochloride 
solution 12 mg/mL. Sixteen diltiazem hydrochloride 
tablets of 90 mg were triturated and added to a mixture 
of 60 mL Ora-Sweet® and 60 mL Ora-Plus® (1:1). The 
preparation was stored in amber PET bottles at 5 °C and 
25 °C in the absence of light. After 60 days, an average 
of at least 92% of the initial concentration of diltiazem 
hydrochloride remained stable in the preparation (Allen, 
Erickson, 1996a).
Lisinopril
Thompson et al. (2003) studied the stability of 
1 mg/mL lisinopril suspension prepared from commercially 
available tablets. Lisinopril is an angiotensin converting 
enzyme (ACE) inhibitor and when administered orally 
the absorption is slow, variable and incomplete that is not 
reduced by the presence of food. Lisinopril is indicated 
for the treatment of hypertension, heart failure and post-
myocardial infarction. The suspension was prepared 
by addition of purified water and the tablets previously 
triturated in amber polyethylene terephthalate (PET) 
bottle. The suspension was shaken by hand. Subsequently, 
the following vehicles were added gradually: Bicitra® and 
Ora-Sweet SF®, shaking the bottle after each addition. 
The suspension was stored at 25 °C under ambient light. 
After 4 weeks of storage, the concentration of lisinopril 
was 99% (Thompson et al., 2003).
Metoprolol
Yamreudeewonget, Dolence and Pahlconducted 
(2006) analyzed the stability of extemporaneous solutions 
metoprolol tartrate prepared from tablets. Metoprolol 
tartrate is a selective antagonist of β1-adrenergic receptors. 
It is widely used in the treatment of hypertension, angina 
pectoris, post-infarction, heart failure, cardiac arrhythmia, 
hyperthyroidism (as adjunctive medication) and in 
prophylaxis of migraine. To prepare the solution were 
used three tablets of metoprolol tartrate 100 mg, which 
were triturated in a mortar and 20 mL of deionized water 
was added to form a paste. After this first step, were added 
80 mL of sorbitol solution 70% and deionized water 
to the volume of 240 mL. The solution obtained was 
highly viscous and with a concentration of 1.25 mg/mL 
metoprolol tartrate. Part of the solution was stored in 
an amber PET bottle at 22-26 °C and another part at 
4-8 °C for 8 weeks. During this period there was no 
significant decrease in metoprolol concentration in the 
extemporaneous solutions. The results found were ± 10% 
of the initial concentration (Yamreudeewonget, Dolence, 
Pahl, 2006).
Moxifloxacin
The stability of a 20 mg/mL moxifloxacin suspension 
was studied by Hutchinson, Johnson and Klein. To prepare 
the suspension, three moxifloxacin tablets 400 mg were 
triturated using a mortar of glass until obtaining a fine 
powder. 30 mL of Ora-Plus® and Ora-Sweet® were added 
to the fine powder. The suspension was stored in an amber 
plastic bottle at 23-25 °C for 90 days. At least 99% of the 
initial concentration of moxifloxacin remained stable for 
90 days (Hutchinson, Johnson, Klein, 2009).
Propafenone
Propafenone is an antiarrhythmic drug indicated 
for the treatment of symptomatic supraventricular 
tachyarrhythmia. Studies indicate that propafenone is a 
relatively safe drug for supraventricular tachycardia in 
pediatric patients: however, the approval and admission 
of propafenone for clinical use in children are restricted 
due to the limited number of studies involving the pediatric 
population (Olguín, 2008). In a study carried out in Mexico 
by Olguín (2008); the stability of an extemporaneous 
suspension of 1.5 mg/mL propafenone was determined. 
To prepare the suspension, 150 mg of propafenone tablet 
was triturated to a fine powder in a mortar, and then 
100 mL of pomegranate syrup was added. The suspension 
was placed in an amber glass flask, where one flask was 
stored at 3-5 °C and the other at 15 ± 5 °C. In both storage 
conditions, the suspension remained stable for 90 days. 
The percentage of concentration of suspension storage 
at 3-5 °C was around 90% and for suspension storage at 
15 ± 5 °C it was above 90% (Olguín, 2008).
Ribavirin
Ribavirin is a synthetic nucleoside with structure 
similar to that of guanosine. This drug acts by altering 
the reservoirs of viral nucleotides or by interfering with 
the synthesis of viral messenger RNA. It is used to treat 
all forms of viral hepatitis and Lassa fever (Chan, Tong, 
Chow, 2004). In a study conducted by Chan, Tong and 
Chow, the stability of a 40 mg/mL ribavirin suspension 
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was determined. To prepare the suspension, solutions 
of benzoic acid and hydroxybenzoate were used. The 
benzoic acid solution was prepared by trituration of 50 g of 
benzoic acid with 750 mL of propylene glycol using pestle 
and mortar. The mixture was transferred to a flask and 
purified water was added to obtain a volume of 1000 mL. 
After that, 8 g of methyl hydroxybenzoate and 2 g of 
propyl hydroxybenzoate were triturated with 100 g of 
propylene glycol for the preparation of hydroxybenzoate 
solution. The solution was transferred to a flask. To 
prepare the suspension of ribavirin it is recommended 
that the manipulator uses safety glasses, protective 
clothing, gloves and face mask. All procedure should be 
performed in a flow hood, due to antiviral toxicity. The 
suspension was prepared by trituration into a mortar of 
1.25 mg powdered tragacanth, 2 mL of 90% (v/v) alcohol 
and a little amount of distilled water was added until a 
homogeneous paste was obtained. Then, the contents of 
20 capsules of ribavirin 200 mg were added in the paste 
and triturated. The mixture was transferred to a flask which 
was added with 2 mL of the benzoic acid solution, 1 mL of 
the hydroxybenzoate solution and distilled water to obtain 
a final volume of 100 mL. The suspension was stored in 
the refrigerator at 4 °C and for 28 days remained stable. 
The percentage of concentration was above 90% (Chan, 
Tong, Chow, 2004).
Many hospitalized patients are not able to swallow 
capsules and tablets. Most of these patients are children, 
elderly, bedridden and nasogastric tube users. The 
situational analysis to obtain the liquid oral dosage form 
is important for the pharmacist in the hospital (Glass, 
Haywo, 2006) (Figure 1).
The situational analysis to prepare the liquid oral 
dosage form should be carried out in the following 
situations (Glass, Haywo, 2006; Jackson, Lowey, 2010):
1 - Initially, the pharmacist must start from the 
principle that the prescribed drug is available in liquid 
oral dosage form (solution, drops, syrup) (Figure 1/
situation 1). In the absence of liquid oral dosage form, an 
alternative pharmaceutical form, as a dispersible tablet 
or suppository, may solve the problem (Figure 2). In the 
absence of these pharmaceutical forms, the alternative is 
the transformation of the pharmaceutical form. For some 
drugs in liquid oral form, the lack of clinical studies and 
safety information can compromise the patient safety. The 
extemporaneous preparation of liquid oral from solid oral 
and subsequent administration to the patient should be 
performed in hospital environment with supervision of a 
multidisciplinary group composed of doctors, nurses and 
pharmacists.
2 - In the absence of the prescribed medication, the 
multidisciplinary group must discuss the existence of a 
therapeutic alternative in liquid oral dosage form for the 
solution of the problem (Figure 1/situation 2). However, in 
some situations the drug is orphan (unique) and there are 
no therapeutic alternatives. In case liquid oral dosage form 
is not available, it is necessary to prepare extemporaneous 
liquid from solid oral dosage form. 
3 - The search related to drugs in liquid oral form is 
performed in official compendia, such as pharmacopoeias 
and national formularies (Figure 1/situation 3). The most 
used are the Brazilian Pharmacopoeia (2010), Handbook 
of Extemporaneous Preparation: a guide to pharmaceutical 
compounding (Jackson, Lowey, 2010); National 
Formulary of Brazilian Pharmacopoeia (2012), Portuguese 
Galenic Formulary (2005) and Pediatric Pharmacopoeia 
(1998). These official compendiums report suggestions of 
liquid oral formulation with stability studies containing 
expiration date, storage conditions and packaging. This 
alternative should be investigated prior to the preparation 
of liquid oral formulation from tablet trituration or capsule 
opening, because such practice is not supervised by any 
health regulatory agency. The manipulation of liquid oral 
formulations prepared from tablets trituration or capsules 
opening should be performed considering the stability, 
incompatibilities, literature information and release forms 
such as controlled release. The use of tablets and capsules 
with modified release for the preparation of oral liquid 
formulations should be avoided. 
4 - In the absence of liquid oral formulation in 
pharmacopoeias and formularies, the pharmacist can 
search for the formulations in the scientific literature 
(Figure 1/situation 4), such as books (Fernandez, 
Atienza, 2002; Jackson, Lowey, 2010; Jew et al., 2010), 
and scientific journals (Mcrorie, 1996; Nahata, 1999; 
Brion, Nunn, Rietour, 2003; Nunn, Williams, 2005; 
FIGURE 1 - Situational analysis to the preparation of 
extemporaneous oral liquid (Glass, Haywo, 2006).
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Glass, Haywood, 2013; Johohann, Mastroianni, 2016; 
Campbell, Vallejo, 2015; Mimouni, Van der Anker, 
2015; Dijkers et al., 2017; Roque, 2017). A bibliographic 
research in database may indicate scientific articles that 
contain suggestions of formulation with stability study.
5 - In the absence of formulation and stability 
studies in the scientific literature, the pharmacist is 
challenged to develop the liquid oral formulation and 
the stability following scientific principles (Figure 1/
situation 5). The analysis of the following parameters 
must be checked: stability of the drug in the solvent 
(water, buffer or syrup), stability of the drug in relation 
to the environment (oxidation, photodegradation, and 
hydrolysis); the drug and excipient interactions (solvent, 
thickening agent, sweetener, colorant, complexing, 
antioxidant and preservative), incompatibilities between 
drug and packaging material composition (glass or 
plastic), and storage stability (light, temperature and 
humidity) (Jackson, Lowey, 2010). The ideal condition 
is the preparation of liquid oral form using the drug 
powder (Figure 2). In the impossibility of the drug 
powder acquisition, it is necessary to prepare the liquid 
oral formulation from the solid oral (tablet or capsule) by 
the pharmacist. It is necessary the technical knowledge 
of the formulation of tablet or capsule to prevent from the 
excipients in the solid form degrade the drug in the liquid 
oral formulation. Often, the tablet and capsule excipients 
do not degrade the drug, allowing the preparation of liquid 
oral formulation. 
6 - When the development of the liquid oral 
formulation is infeasible due to instability of the drug 
in aqueous vehicle, the alternatives for the pharmacist 
involve the extemporaneous preparation of the liquid oral 
formulation from (Figure 1/situation 6) (Glass, Haywo, 
2006; Jackson, Lowey, 2010; World Health Organization, 
2011b): 6.1 - Tablet trituration and addition to vehicle 
(water, buffer and syrup) for dispersion (Figure 3); 
6.2 - Capsule opening and addition to vehicle (water, 
buffer, syrup) for dispersion; 6.3 - Tablet trituration and 
addition to diluents such as lactose or starch to adjust the 
dosage and capsule filling. Subsequent extemporaneous 
preparation of the liquid oral formulation from capsule 
opening and addition of vehicle (water, buffer, syrup) 
for dispersion. A viable alternative is tablet trituration 
or capsule opening and subsequent addition to food or 
beverage. However, this practice is not recommended 
due to the drug-food interaction that may cause decreased 
absorption and bioavailability (Glass, Haywood, 2006; 
Jackson, Lowey, 2010). 
The trituration of tablets or opening of capsules with 
modified release is not recommended (Table II).
Tablet trituration is permitted for tablets without 
functional coating. Tablets that contain gastro-resistant 
coat or with sustained release matrix should not be 
triturated, because this practice is dangerous and exposes 
the patients to health risk (Jackson, Lowey, 2010): 1 - 
drug degradation resulting in low absorption and absence 
of pharmacological effect; 2 - immediate release of high 
FIGURE 2 - Preparation of the oral liquid formulation from 
drug powder.
FIGURE 3 - Preparation of the oral liquid formulation from 
tablet or capsule.
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doses and subsequent plasmatic concentration that exceeds 
the toxic concentration, resulting in adverse effects. 
Furthermore, addition of powder from tablet or capsule 
in a bottle with water to obtain a solution or suspension 
may generate an unpleasant taste to the patient, besides 
problems related to drug stability. 
The use of sterile solutions or suspensions is not 
recommended (Figure 4), because the excipients may 
cause adverse effects when administered by oral route. 
Sterile solutions or suspensions may contain propylene 
glycol, which has a laxative activity when administered 
orally, example: diazepam injectable sterile solution 
(Garcia-Palop et al., 2016) and still, may contain 
polysorbate 20 and 80, leading to renal dysfunction, and 
hepatomegaly (Cuzzolin, 2018). However, the preparation 
of oral solutions from sterile solutions or suspensions is 
feasible when the drug and the excipients are not irritant 
or toxic to the gastrointestinal mucosa, example: injection 
of vancomycin hydrochloride (Ensom, Decarie, Lakhani, 
2010).
CONCLUSION
The development of extemporaneous oral liquid 
in the hospital environment to the elderly, children, 
nasogastric tube and bedridden patients can be performed 
from the knowledge of incompatibilities, stability and 
toxicity of the drug in liquid oral form. In addition, 
information about the patient age and disease is important 
for the correct choice of vehicle for the liquid oral 
formulation. As discussed previously, it is not possible 
to administer to newborns many types of excipients, 
such as; sweeteners, preservatives and dyes. Solutions 
containing sugars and salts should not be administered 
to diabetic and hypertensive patients, respectively. The 
difficulty in swallowing by elderly, children, bedridden 
and nasogastric tube patients requires the administration 
of liquid oral formulations, which are often not available 
in the market. Any factor that compromises the stability 
of the drug in aqueous vehicle and consequently patient 
safety is a barrier to the development of the formulation. 
Thus, the preparation of extemporaneous liquid oral from 
solid oral dosage form is performed based on information 
from official compendium or scientific literature. This 
article of review is a guide containing information about 
the preparation and stability of extemporaneous oral liquid 
for use in hospital clinical practice. 
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